Advertisement

Latest news

Clinical Trials – September 30, 2024

Cereno signs agreement with Fluidda and announces Phase IIa results 

Cereno Scientific has signed an agreement with medical technology company Fluidda on Respiratory Imaging solutions, with the aim to visualize signs of reverse remodeling of lead drug candidate CS1 in Pulmonary Arterial Hypertension (PAH) in a clinical setting.

Pharma Business – October 2, 2024

AstraZeneca’s Enhertu granted Priority Review in the US

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy.

Financing – October 2, 2024

Spago Nanomedical enters a new phase

The Board of Directors of Spago Nanomedical has decided that the company’s resources will be focused on the development of Tumorad with the company’s primary priority being the execution of the ongoing clinical study Tumorad-01 with the candidate drug 177Lu-SN201.

Financing – October 2, 2024

Senzime carries out a directed share issue of SEK 86 million

The board of directors of Senzime has resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of SEK 6.20 per share.

Financing – October 2, 2024

Sanofi invests in Vicore

Vicore Pharma Holding has announced an investment from Sanofi in Vicore through a commitment to subscribe for shares in the ongoing rights issue corresponding to a total of approximately USD 10 million.

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.